OBJECTIVES: Patient preference strongly influences long-term medication use in chronic diseases such as postmenopausal osteoporosis. METHODS: This 6-month, open-label, crossover, international study randomized 350 women with postmenopausal osteoporosis to monthlyoral ibandronate 150mg for 3months followed by weekly alendronate 70mg for 12weeks, or vice versa. RESULTS: Of patients expressing a preference (93.1%), more preferred the monthly ibandronate regimen (70.6%) than the weekly alendronate regimen (29.4%). The monthly ibandronate preference rate was statistically significant (P<0.0001). The most common reasons for ibandronate preference were ease of staying on treatment long-term (81.5%) and better lifestyle fit (75.4%). More women found the monthly ibandronate regimen more convenient (76.6%) than the weekly alendronate regimen (23.4%). The monthly ibandronate convenience rate was statistically significant (P<0.0001). The safety profiles of the two regimens were similar. CONCLUSION: The strong patient preference for monthly ibandronate over weekly alendronate replicates previous study findings and may lead to improved treatment adherence in women with postmenopausal osteoporosis.
RCT Entities:
OBJECTIVES:Patient preference strongly influences long-term medication use in chronic diseases such as postmenopausal osteoporosis. METHODS: This 6-month, open-label, crossover, international study randomized 350 women with postmenopausal osteoporosis to monthly oral ibandronate 150mg for 3months followed by weekly alendronate 70mg for 12weeks, or vice versa. RESULTS: Of patients expressing a preference (93.1%), more preferred the monthly ibandronate regimen (70.6%) than the weekly alendronate regimen (29.4%). The monthly ibandronate preference rate was statistically significant (P<0.0001). The most common reasons for ibandronate preference were ease of staying on treatment long-term (81.5%) and better lifestyle fit (75.4%). More women found the monthly ibandronate regimen more convenient (76.6%) than the weekly alendronate regimen (23.4%). The monthly ibandronate convenience rate was statistically significant (P<0.0001). The safety profiles of the two regimens were similar. CONCLUSION: The strong patient preference for monthly ibandronate over weekly alendronate replicates previous study findings and may lead to improved treatment adherence in women with postmenopausal osteoporosis.
Authors: D L Kendler; M R McClung; N Freemantle; M Lillestol; A H Moffett; J Borenstein; S Satram-Hoang; Y-C Yang; P Kaur; D Macarios; S Siddhanti Journal: Osteoporos Int Date: 2010-09-09 Impact factor: 4.507
Authors: P Hadji; D Gamerdinger; W Spieler; P H Kann; H Loeffler; K Articus; R Möricke; V Ziller Journal: Osteoporos Int Date: 2011-03-26 Impact factor: 4.507
Authors: E Barrett-Connor; S W Wade; T P Do; S Satram-Hoang; R Stewart; G Gao; D Macarios Journal: Osteoporos Int Date: 2011-04-06 Impact factor: 4.507
Authors: D L Kendler; L Bessette; C D Hill; D T Gold; R Horne; S F Varon; J Borenstein; H Wang; H-S Man; R B Wagman; S Siddhanti; D Macarios; H G Bone Journal: Osteoporos Int Date: 2009-08-06 Impact factor: 4.507